Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Although not a practice changing study, this study makes a few points that may be seen in future studies. In the setting of biochem-recurrent prostate cancer after RP, novel anti-androgen agents may replace ADT in combination with salvage XRT as they appear to be active and less toxic than traditional ADT. Low/Intermediate risk patients are likely of benefit with median PSA at accrual of 0.3 in this study, not unlike other similar studies. The role of combination anti-hormone therapy + salvage radiation seems to be solidifying.
1 thought on “Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men”
A large retrospective VA study presented at ASCO 2020 reported increased MACE and more so with Agonists than antagonists. So I am skeptical about this EMR review data and it dose not differentiate Agonist vs antagonist; For patients with pre-existing or high risk I choose direct antagonists than agonists. Also to be noted there are increasing data that Abiratarone is associated with increase cardiovascular events.